Bio-Techne Corporation logo
TECHBio-Techne Corporation

Balance Sheet

Assets, liabilities, and equity analysis

Quarterly Balance Sheet (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
Total Current Assets
688.050M688.050M637.432M609.507M608.300M627.240M634.640M648.567M617.419M
209.819M209.819M172.879M144.962M162.186M140.670M177.549M187.540M151.791M
Short-Term Investments
0.000.000.000.000.000.000.000.001.072M
Cash & Short-Term Investments
209.819M209.819M172.879M144.962M162.186M140.670M177.549M187.540M152.863M
217.916M217.916M184.614M183.897M206.876M237.140M217.940M223.688M241.394M
201.175M201.175M205.447M203.188M189.446M191.083M188.373M185.041M179.731M
2.551B2.551B2.523B2.526B2.558B2.644B2.670B2.736B2.704B
301.306M301.306M302.632M311.059M319.118M335.766M335.136M343.160M342.439M
977.800M977.800M980.561M978.912M980.935M968.612M964.607M982.585M972.663M
Intangible Assets
319.074M319.074M334.990M350.107M365.599M443.699M461.051M486.004M507.081M
Long-Term Investments
254.147M254.147M250.036M266.351M250.983M254.515M256.354M256.308M242.337M
Total Current Liabilities
153.278M153.278M140.426M144.545M175.849M169.204M161.256M142.128M159.379M
23.490M23.490M26.269M30.157M25.311M31.644M33.120M31.559M37.968M
14.181M14.181M0.000.000.000.000.000.000.00
Total Liabilities
465.297M465.297M511.710M560.334M639.060M626.234M591.932M597.367M635.017M
200.000M200.000M260.000M300.000M346.000M330.000M300.000M300.000M319.000M
290.322M290.322M350.895M394.473M444.058M423.499M395.127M398.918M419.538M
Net Debt (Cash)
80.503M80.503M178.016M249.511M281.872M282.829M217.578M211.378M267.747M
2.085B2.085B2.011B1.966B1.919B2.018B2.078B2.139B2.069B
Common Stock
1.565M1.565M1.559M1.557M1.550M1.568M1.579M1.589M1.582M
1.145B1.145B1.107B1.083B1.066B1.196B1.287B1.341B1.325B
4.494.494.544.223.463.713.944.563.87
0.140.140.170.200.230.210.190.190.20

Annual Balance Sheet (USD)

Annual Report
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
06/30/2020
06/30/2019
06/30/2018
Total Current Assets
608.300M617.419M621.482M605.556M510.606M520.920M412.607M398.366M
162.186M151.791M180.571M172.567M199.091M146.625M100.886M121.990M
Short-Term Investments
0.001.072M23.739M74.462M32.463M124.268M65.147M59.764M
Cash & Short-Term Investments
162.186M152.863M204.310M247.029M231.554M270.893M166.033M181.754M
206.876M241.394M218.468M194.548M145.385M122.534M137.466M120.296M
189.446M179.731M171.638M141.123M116.748M103.152M91.050M85.648M
2.558B2.704B2.639B2.295B2.263B2.028B1.884B1.593B
319.118M342.439M324.526M288.798M281.741M248.294M154.039M145.348M
980.935M972.663M872.737M822.101M843.067M728.308M732.667M597.890M
Intangible Assets
365.599M507.081M534.645M531.522M615.968M516.545M579.429M446.332M
Long-Term Investments
250.983M242.337M255.857M0.000.000.00-89.754M2.660M
Total Current Liabilities
175.849M159.379M128.509M176.018M152.284M106.668M101.985M78.690M
25.311M37.968M25.679M33.865M29.384M23.090M16.210M18.452M
0.000.000.0012.500M12.500M12.500M12.500M0.00
Total Liabilities
639.060M635.017M672.176M593.794M691.723M646.397M718.821M514.057M
346.000M319.000M350.000M243.410M328.827M344.243M492.660M339.000M
444.058M419.538M454.965M325.971M420.554M433.526M505.160M339.000M
Net Debt (Cash)
281.872M267.747M274.394M153.404M221.463M286.901M404.274M217.010M
1.919B2.069B1.967B1.702B1.563B1.381B1.166B1.079B
Common Stock
1.550M1.582M1.576M1.566M390K385K379K376K
1.066B1.325B1.309B1.123B1.085B1.057B931.934M876.931M
3.463.874.843.443.354.884.055.06
0.230.200.230.190.270.310.430.31

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman